Trieste, 29 January 2025 - Ulisse Biomed S.p.A announces the signing of a new partnership agreement with CapeBIO.
CapeBIO is a South African company, a leader in the biotech sector, with strong research and development capabilities and an established track record in the commercialisation of molecular biology diagnostic tests.
The agreement initially involves the commercialisation of Ulysses Biomed's proprietary HPV screening and genotyping solutions, as well as the Hyris™ system, a proprietary hardware and software platform for genetic analysis.
The agreement is exclusive to the South African market.
"We are proud to start this commercial collaboration with CapeBIO in order to develop the South African market with such an innovative partner," says Gabriele Salaris, Head of Marketing & Sales at Ulisse Biomed. "Our goal is to start with the commercialisation of our existing solutions for HPV screening and typing, but we already foresee great opportunities to go further by collaborating on the development of new tests that meet the needs of the African market," Salaris concludes.
"This partnership is long-term and meets our strategic objectives of leveraging technologies from international partners to enhance our immediate market offerings, creating a critical mass of technologies that complement our current offerings. We are also excited to exchange the two companies' research and development capabilities, know-how and efforts to accelerate high-impact innovations and their commercialisation," adds Daniel Ndima, CEO of Capebio.
